



New generation accelerator for IBA Proteus®ONE receives CE mark authorization

Centre Antoine-Lacassagne (CAL) in Nice ready to treat patients soon

Louvain-La-Neuve, Belgium, March 30, 2016 – IBA (Ion Beam Applications SA), the world's leading provider of Proton Therapy solutions for the treatment of cancer, has recently received CE mark authorization of its new super conducting accelerator. The accelerator is the latest development of the *Proteus®ONE**, IBA's compact Intensity Modulated Proton Therapy (IMPT) system, that needed approval from competent authorities.

CE Marking was a necessary step towards the acceptance of the first Proteus®ONE in Europe, which is located at the Centre Antoine-Lacassagne (CAL) in Nice, France. In less than three months, in June 2016, the Center will be fully accepted with all necessary certifications.

IBA has signed another five additional contracts to provide Proteus®ONE in Europe, with a total of 12 Centers sold worldwide. The recent CE marking is an important milestone that will ensure on time delivery of all of IBA's current and future contracts and underscores the fact that for this type of system, IBA has the fastest delivery times in the world.

Frederic Genin, Proton Therapy Chief Marketing Officer shared, "IBA has developed the only compact system optimized for image guided IMPT. This new market segment allows us to fulfil our mission to locate Proton Therapy within the reach of communities everywhere. The number of orders we have from Europe and the imminence of the first treatment on our system shows that we deliver on our promises. This will strengthen our leadership in the compact segment of the market and will accelerate our market penetration into Europe, as ours is the only compact certified IMPT system currently available."

Gregory Saive, ProteusONE Product Manager, commented on the achievement, "Getting the CE marking for our new Proton Therapy Synchro-Cyclotron is crucial to our ProteusONE plans. This milestone endorses IBA's quality and professionalism, especially as we've been able to obtain regulatory approval in record time, before any other Proton Therapy vendor. I am happy to be in charge of this wonderful compact solution which makes Proton Therapy more accessible and affordable to more people"

The ProteusONE is the world only CE marked compact IMPT system. With IBA's industrialized production together with full CE approval, IBA is now able to install complete systems in less than 12 months.

About Proteus®ONE

Proteus®ONE comprises the latest technologies in Proton Therapy, making it the ideal platform for Research and Development purposes. Proteus®ONE is smaller, more affordable, easier to install and operate and is ultimately easier to finance than most common solutions. All these attributes make our Proton Therapy solution accessible to more and more Healthcare Institutions worldwide. Proteus®ONE is equipped with Pencil Beam Scanning, a technology that offers high sub-millimeter precision treatment, which allows delivery of very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue.

**Proteus®ONE is the brand name of a new configuration of the Proteus® 235*



For further information please contact:

IBA

Jana Kulhankova
Marketing Associate Proton Therapy
+32 10 203652
jana.kulhankova@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com